Abstract
Previous studies have shown that the miR-17-92 cluster is involved in the occurrence and development of bladder cancer. However, the role of serum miR-17-92 cluster in the diagnosis of bladder cancer has not been studied. In the present study, we evaluated the expression of miR-17-92 cluster members in bladder cancer tissues by analyzing 428 cases from TCGA database. Next, we collected the sera of 74 bladder cancer patients and 90 controls, and used qRT-PCR to detect the relative expression of the cluster. The results showed that the expression of the cluster members in the sera of patients were significantly higher than that of the controls, and they were positively correlated with the clinical stage and pathological grade of the patients. We evaluated their ability to diagnose bladder cancer using ROC, of which miR-92a-3p (AUC = 0.902), miR-17-5p (AUC = 0.845) and miR-20a-5p (AUC = 0.806) were the most prominent. Finally, we established a diagnostic model by logistic regression (AUC = 0.969). We further validated the results of the study using another dataset from the GEO database. Moreover, we evaluated the prognostic value of the cluster. The results revealed that miR-20a-5p was correlated with recurrence of bladder cancer. In summary, the present study validated the overexpression of serum miR-17-92 cluster in bladder cancer. The model composed of the three cluster members were confirmed to be a promising noninvasive biomarker for bladder cancer diagnosis.
Highlights
Bladder cancer (BC) is the sixth most common cancer worldwide, with the eighth highest mortality rate [1]
Expression of miR-17-92 Cluster Members Was Remarkably Elevated in BC
Biomarkers in urine may be useful in estimating residual illness or recurrence of bladder cancer; liquid biopsy in urine may be a valuable source of personalized medicine prognostic biomarkers [19]
Summary
Bladder cancer (BC) is the sixth most common cancer worldwide, with the eighth highest mortality rate [1]. Little improvement in the diagnosis and treatment of BC has been made over the past three decades, unlike many other tumors [2]. The main reason was that the existing diagnostic methods for BC cannot meet the needs of clinical work. A good BC diagnosis method can help the early diagnosis and treatment of BC, but can monitor the recurrence after surgery. Cystoscopy is the gold standard for detecting BC, but its detection method is invasive [3]. It is usually accompanied by risks of bleeding, UTI, and difficulty urinating, so it is not
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
